Gotham Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-12,885
Closed -$197K 1727
2025
Q3
$197K Sell
12,885
-37,227
-74% -$484K ﹤0.01% 1619
2025
Q2
$443K Sell
50,112
-6,285
-11% -$55.2K ﹤0.01% 1355
2025
Q1
$442K Buy
+56,397
New +$472K ﹤0.01% 1269

Other funds holding AVDL

Gotham Asset Management's AVDL Position: Q4 2025 in Review

Gotham Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 12,885 shares — an estimated $197K sold.

Gotham Asset Management first reported a position in AVDL in Q1 2025 and held it in 3 quarters. The position peaked at $443K in Q2 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Gotham Asset Management reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Gotham Asset Management sold 12,885 Avadel Pharmaceuticals shares in Q4 2025, an estimated $197K.
  • Gotham Asset Management first reported a position in Avadel Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Gotham Asset Management's Avadel Pharmaceuticals position peaked at $443K in Q2 2025.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Gotham Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.